Welgene Biotech Co.,Ltd. (6661.TWO)

TWD 18.15

(-0.55%)

Operating Income Summary of Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.'s latest annual operating income in 2023 was -4.25 Million TWD , down -110.31% from previous year.
Welgene Biotech Co.,Ltd.'s latest quarterly operating income in 2024 Q2 was -1.01 Million TWD , up 79.84% from previous quarter.
Welgene Biotech Co.,Ltd. reported an annual operating income of 16.61 Million TWD in 2022, up 36.47% from previous year.
Welgene Biotech Co.,Ltd. reported an annual operating income of 12.17 Million TWD in 2021, down -68.53% from previous year.
Welgene Biotech Co.,Ltd. reported a quarterly operating income of -5 Million TWD for 2024 Q1, down -108.53% from previous quarter.
Welgene Biotech Co.,Ltd. reported a quarterly operating income of -2.4 Million TWD for 2023 Q4, down -299.67% from previous quarter.

Annual Operating Income Chart of Welgene Biotech Co.,Ltd. (2023 - 2014)

Historical Annual Operating Income of Welgene Biotech Co.,Ltd. (2023 - 2014)

Year	Operating Income	Operating Income Growth
2023	-4.25 Million TWD	-110.31%
2022	16.61 Million TWD	36.47%
2021	12.17 Million TWD	-68.53%
2020	38.68 Million TWD	-5.65%
2019	41 Million TWD	7.05%
2018	38.3 Million TWD	39.03%
2017	27.54 Million TWD	215.23%
2016	8.73 Million TWD	-64.46%
2015	24.59 Million TWD	-27.4%
2014	33.87 Million TWD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-1.01 Million TWD	79.84%
2024 Q1	-5 Million TWD	-108.53%
2023 Q4	-2.4 Million TWD	-299.67%
2023 FY	-1.71 Million TWD	-110.31%
2023 Q1	-5.01 Million TWD	-205.49%
2023 Q2	6.3 Million TWD	225.75%
2023 Q3	-601 Thousand TWD	-109.54%
2022 Q2	17.63 Million TWD	491.1%
2022 Q4	-1.64 Million TWD	-131.98%
2022 Q3	5.12 Million TWD	-70.91%
2022 Q1	-4.5 Million TWD	-142.01%
2022 FY	16.61 Million TWD	36.47%
2021 Q3	1.43 Million TWD	-75.03%
2021 FY	12.17 Million TWD	-68.53%
2021 Q4	10.73 Million TWD	649.3%
2021 Q1	-5.72 Million TWD	-149.04%
2021 Q2	5.73 Million TWD	200.19%
2020 FY	38.68 Million TWD	-5.65%
2020 Q4	11.67 Million TWD	-0.68%
2020 Q3	11.75 Million TWD	6.47%
2020 Q2	11.03 Million TWD	161.17%
2020 Q1	4.22 Million TWD	-73.31%
2019 FY	41 Million TWD	7.05%
2019 Q4	15.83 Million TWD	17.26%
2019 Q3	13.5 Million TWD	166.77%
2019 Q2	5.06 Million TWD	0.0%
2019 Q1	5.06 Million TWD	-68.84%
2018 Q2	3.23 Million TWD	0.0%
2018 FY	38.3 Million TWD	39.03%
2018 Q1	3.23 Million TWD	-65.89%
2018 Q3	16.24 Million TWD	401.54%
2018 Q4	16.24 Million TWD	0.0%
2017 Q3	9.49 Million TWD	83.31%
2017 Q2	5.18 Million TWD	0.0%
2017 Q4	9.49 Million TWD	0.0%
2017 FY	27.54 Million TWD	215.23%
2017 Q1	5.18 Million TWD	-18.96%
2016 FY	8.73 Million TWD	-64.46%
2016 Q4	6.39 Million TWD	0.0%
2016 Q3	6.39 Million TWD	905.82%
2016 Q2	635.5 Thousand TWD	0.0%
2016 Q1	635.5 Thousand TWD	0.0%
2015 FY	24.59 Million TWD	-27.4%
2014 FY	33.87 Million TWD	0.0%

Peer Operating Income Comparison of Welgene Biotech Co.,Ltd.

Name	Operating Income	Operating Income Difference
BIONET Corp.	84.69 Million TWD	105.029%
DIVA Laboratories, Ltd.	92.15 Million TWD	104.622%
Genetics Generation Advancement Corp.	18.57 Million TWD	122.927%
Puriblood Medical Co., Ltd.	-50.4 Million TWD	91.55%
TFBS Bioscience Inc.	-4.45 Million TWD	4.357%